The signal peptide as a new target for drug design
- PMID: 32209293
- PMCID: PMC7138182
- DOI: 10.1016/j.bmcl.2020.127115
The signal peptide as a new target for drug design
Abstract
Many current and potential drug targets are membrane-bound or secreted proteins that are expressed and transported via the Sec61 secretory pathway. They are targeted to translocon channels across the membrane of the endoplasmic reticulum (ER) by signal peptides (SPs), which are temporary structures on the N-termini of their nascent chains. During translation, such proteins enter the lumen and membrane of the ER by a process known as co-translational translocation. Small molecules have been found that interfere with this process, decreasing protein expression by recognizing the unique structures of the SPs of particular proteins. The SP may thus become a validated target for designing drugs for numerous disorders, including certain hereditary diseases.
Keywords: CADA; CD4; ER; Hereditary diseases; Inhibitor; Protein; Sec61; Signal peptide; Sortilin; Translocation.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this publication.
Figures
References
-
- Patrick G.L. 5th ed. Oxford University Press; Oxford, UK: 2013. An Introduction to Medicinal Chemistry.
-
- Hopkins A.L., Groom C.R. Opinion: the druggable genome. Nat Rev Drug Discov. 2002;1:727–730. - PubMed
-
- Chen X.P., Du G.H. Target validation: a door to drug discovery. Drug Discov Ther. 2007;1:23–29. - PubMed
-
- Deweerdt S. RNA therapies explained. Nature. 2019;574:S2–S3.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Chemical Information
Research Materials
